Merck Specialities appoints Pratima Reddy as MD of India

Merck today announced the appointment of Pratima Reddy as the Managing Director for Merck Specialities Pvt. Ltd, the healthcare business of Merck KGaA, Darmstadt in India. Pratima will lead India’s healthcare strategy and operations, effective August 1, 2022, as successor to Anandram Narasimhan, transitioning into a regional role at APAC. In his role, Anand has steered India and the Emerging Frontier Markets organization to a strong marker, beating growth across therapeutic areas.

Before taking over as the Managing Director of India Operations, Pratima was the Regional Franchise Leader (RFL) of the Cardiovascular, Metabolism and Endocrinology (CM&E) franchise in APAC. An active member of the APAC Leadership team, her efforts have ensured that the CM&E franchise continues to grow in the region and continues its market leadership despite market challenges.

An outcome-oriented leader with demonstrated ability to work across cultures, and business areas, she focuses on creating positive impact across the organisation. “I am privileged to be chosen for this role. Today, more than ever, we need to realize and fulfil our responsibility to improve the overall healthcare ecosystem by working towards providing advanced medical care to patients.” said Pratima Reddy, MD, Merck Specialities Pvt. Ltd.

Pratima has an extensive experience of over 17 years, with nine years in the pharmaceutical industry, including varied roles across functions in national and global teams since joining Merck in October 2013. In addition, she headed the Oncology unit in the country, where she led the turnaround of the Oncology business by demonstrating the opportunity to drive strong growth via focused access strategies.
MB Bureau